2008 issue 2

Back

Volume 17, issue 2

Review article

Flurbiprophene and its derivatives in the treatment of dementia in the course of Alzheimer’s disease

Tadeusz Pietras1, Maciej Banasiak1, Wojciech Musiał1
1. Klinika Pneumonologii i Alergologii Instytutu Medycyny Wewnętrznej Uniwersytetu Medycznego w Łodzi
Postępy Psychiatrii i Neurologii 2008; 17 (2): 145-148
Keywords: dementia, gamma secretase, flurbiprophen

Abstract

Objectives. The aim of this study is to present the state-of-the art research on flurbiprophene and its derivatives in Alzheimer's disease (AD) treatment.
Review. A number of epidemiological studies have suggested that long-term use of some nonsteroidal antiinfammatory drugs may reduce the risk of developing AD and slow down the progress of dementia in the course of this condition. Several studies show that specific agents, including sulindac, indomethacine, flurbiprophene, and ibuprophene, reduce amyloid beta levels in cultured cells of peripheral, glial and neuronal origin. Tarenflurbil, the single R-enantiomer of flurbiprophene, has been shown to lower brain levels of beta-amyloid in animal models of Alzheimer s disease. Preliminary clinical trials suggest that tarenflurbil may protect human brain against amyloid beta aggregation, thus inhibiting cognitive deterioration in AD patients. Flurbiprophene and its derivatives probably modulate gamma secretase activity via selective allosteric inhibition of enzymatic activity.
Conclusions. Flurbiprophene derivatives as allosteric gamma secretase inhibitors may constitute a new class of substances in the pharmacological treatment of Alzheimer's disease.

Address for correspondence:
Dr Tadeusz Pietras
Klinika Pneumonologii i Alergologii Instytutu Medycyny Wewnętrznej Uniwersytetu Medycznego w Łodzi
ul. Kopcińskiego 22, 91-123 Łódź
tel/fax 0(42)6782129
mail: cital200@wp.pl